Exelixis

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

4 drugs in development

Phase 14

By Therapeutic Area

top 1

Oncology

4100%

R&D Momentum

59/100

Pipeline Velocity

19/100

Trial Completion Rate

53/100

Pipeline Concentration

100/100

Pipeline Freshness

61/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners

Activity

Recent Activity

Last 14 days

Sep 11, 2026

Recruiting

A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

Sep 9, 2026

Recruiting

A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Earlier

Aug 26, 2026TrialRandomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Placebo in Participants With Colorectal Cancer With Stage II/III Molecular Residual Disease Following Definitive Therapy

Aug 20, 2026TrialA Phase 1 Dose-Escalation Study of XL092 in Children and Adolescents With Relapsed or Refractory Solid Tumors

Aug 19, 2026TrialLong-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Aug 6, 2026TrialA Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology or Other Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Jul 30, 2026TrialA Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Jul 18, 2026TrialA Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

4 more events

Jun 25, 2026TrialA Phase 1 Dose Escalation and Expansion Study of XB628 as a Single Agent and in Combination With Zanzalintinib in Participants With Advanced or Metastatic Solid Tumors

Jun 24, 2026TrialA Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Aug 18, 2025TrialA Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

May 13, 2025TrialPharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

5 patent groups across drugs · Source: FDA Orange Book

DrugExpires

CometriqAug 14, 2026 Cometriq4 patentsJan 15, 2030 Cometriq2 patentsJul 18, 2031 Cometriq3 patentsFeb 10, 2032 CometriqJul 9, 2033

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Advanced Solid Tumors

XL309

Locally Advanced or Metastatic Solid Tumors

XB010 XB371

Solid Tumor

XB628

Oncology

Advanced Solid Tumors

XL309Phase 1

Locally Advanced or Metastatic Solid Tumors

XB010Phase 1

XB371Phase 1

Solid Tumor

XB628Phase 1

Regulatory

Regulatory Timeline

20121 event

FDANov 29

Cometriq — COMETRIQ

Application NDA203756 (NDA)

20161 event

FDAApr 25

Cometriq — CABOMETYX

Application NDA208692 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)